杜邦完成四笔清洁水技术收购

威尔明顿，德尔。，1月9日，2020年1月9日 -杜邦(NYSE: DD)今日宣布，已完成2019年对Desalitech、inge GmbH、Memcor®和OxyMem Limited的收购;在超滤、反渗透和离子交换树脂等水净化和分离技术领域处于领先地位。

这四次收购支持杜邦的目标是增加对满足全球客户当前和未来挑战所需的产品和技术的目标，包括增加需求来循环水，同时降低产生清洁水的能量要求。

“水资源稀缺是一种全球挑战，需要用紧迫感解决。作为创新水技术的全球领导者，我们不断扩大我们的高质量解决方案的技术组合，以帮助客户净化，保存和重复使用这一宝贵的资源，“杜邦水解决方案副总裁兼总经理HP Nanda表示。亚搏国际网页“我们期待着与设备制造商，最终用户和其他价值链合作伙伴一起使用各种商业模式，解决他们的水挑战并提供卓越的价值。”

最近收购进一步扩大了杜邦的投资组合，提升了公司加速创新的能力，为客户提供更好的服务水平，同时降低了清水的生命周期成本。添加到杜邦水解决方案的四家公司组合包括：亚搏国际网页

• 英奇GmbH是一家,从巴斯夫获得的超滤膜业务。业界领先的多孔PES超滤技术与杜邦的高流量PVDF膜技术相辅相成。这笔交易包括巴斯夫公司约150名国际员工、位于德国格雷芬伯格的总部和生产基地，以及巴斯夫SE拥有的相关知识产权。
• Memcor®,Evoqua Water technologies Corp.的超滤和膜生物反应器(MBR)技术部门。超滤组合的增加拓宽了杜邦的解决方案，膜生物反应器，浸没和加压超滤系统，以及其他新的应用。这笔交易包括在澳大利亚的一家制造工厂和大约200名员工。
• Desalitech Ltd.，闭路反渗透（CCRO）公司。DesaliteCh的CCRO技术解决了核心市场段中的高水恢复需求，如食品和饮料，市政，微电子，动力等。该技术增加了杜邦产品组合，以帮助进一步降低水的生命周期成本，交付超过95％的恢复，并使最终用户可以轻松地在工业和分散设置中的小于中型系统中运行。该交易包括公司（品牌和产品组合），知识产权和40人劳动力。
• OxyMem有限,是一家开发和生产膜曝气生物膜反应器(MABR)技术处理和净化城市和工业废水的公司。该交易包括所有知识产权、60多名员工和位于爱尔兰阿斯隆的一个生产基地。

加入Inge和Memcor投资组合，杜邦成为跨多个市场段的领先的UF供应商，如住宅，工业，公用事业，废水和其他特种解决方案。随着从Desalitech的CCRO，杜邦可以为客户提供更多选择和灵活性，以解决水资源稀缺和净化挑战。随着来自Oxymem的新兴技术，该公司可以更好地支持客户希望降低占地面积和次要废水处理的能源要求。

“这四次收购完全符合我们的战略，即成为领先的水技术供应商，更好地满足全球客户不断变化的需求，”杜邦水解决方案增长和战略总监Nicole Richards说。亚搏国际网页“我们期待与我们的客户和合作伙伴合作，增加获得最好的新分离和净化技术的机会，共同解决全球水危机。”

关于杜邦安全与建筑

杜邦安全与建筑是一种全球领导者，在水，庇护和安全方面提供生命的基本需求的创新;使客户能够通过独特的能力，全球规模和标志性品牌赢得，包括Dupont™Corian®，Kevlar®，Nomex®，Tyvek®，GreatStuff™，泡蛋白酶^™和FilmTec™。有关杜邦水解决方案的更多信息，亚搏国际网页请浏览//www.lufeng-fst.com/water.。

关于杜邦

杜邦公司(NYSE: DD)是全球创新领导者，以科技为基础的材料、配料和解决方案帮助改变工业和日常生活。我们的员工运用不同的科学和专业知识，帮助客户在电子、交通、建筑、水、健康和保健、食品和工人安全等关键市场推进他们的最佳理念，并提供必要的创新。更多信息请访问www.lufeng-fst.com.。

关于前瞻性陈述的警告声明
本函件包含联邦证券法所指的“前瞻性陈述”，包括经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节。在这种情况下，前瞻性陈述通常涉及预期的未来业务、财务业绩和财务状况，并经常包含诸如“期望”、“预期”、“打算”、“计划”、“相信”、“寻求”、“看到”、“将”、“将”、“目标”等词，以及这些词的类似表达和变体或否定形式。

2019年4月1日，本公司通过职业奖励的所有Dow Inc.（“Dow Distribution”的所有杰出股票完成了物料科学业务分为单独和独立的公共公司。）。本公司于2019年6月1日完成了其农业业务将其农业业务分解为一家独立的独立公共公司，以Pro RATA股息的所有股票股票在Corteva，Inc。（“Corteva Distribution”（“Corteva Distribution”））。

On December 15, 2019, DuPont and IIF announced they had entered definitive agreements to combine DuPont’s Nutrition & Biosciences business with IFF in a transaction that would result in IFF issuing shares to DuPont shareholders, pending customary closing conditions, other approvals including regulatory and that of IFF’s shareholders.

前瞻性陈述涉及不同程度，不确定和受风险，不确定性和假设的事项，其中许多超出了杜邦的控制，这可能导致实际结果与任何前瞻性陈述中表达的结果不同。前瞻性陈述不保证未来结果。Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction with IFF; changes in relevant tax and other laws, (ii) failure to obtain necessary regulatory approvals, approval, if required, of IFF’s shareholders, anticipated tax treatment or any required financing or to satisfy any of the other conditions to the proposed transaction, (iii) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the proposed transaction, (iv) risks and costs and pursuit and/or implementation of the separation of the N&B Business, including timing anticipated to complete the separation, any changes to the configuration of businesses included in the separation if implemented, (v) risks and costs related to the Dow Distribution and the Corteva Distribution (together, the “Distributions”) including with respect to achieving all expected benefits from the Distributions; restrictions under intellectual property cross license agreements; non-compete restrictions; incurrence of significant costs in connection with the Distributions, including costs to service debt incurred by the Company to establish the relative credit profiles of Corteva, Dow and DuPont and increased costs related to supply, service and other arrangements that, prior to the Dow Distribution, were between entities under the common control of DuPont; indemnification of certain legacy liabilities of E. I. du Pont de Nemours and Company ("Historical EID") in connection with the Corteva Distribution; and potential liability arising from fraudulent conveyance and similar laws in connection with the Distributions; (vii) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses; (viii) uncertainty as to the long-term value of DuPont common stock; (ix) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade and (x) other risks to DuPont's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the Distributions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could result in a significant operational event for DuPont, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's intellectual property rights; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors. These risks are and will be more fully discussed in DuPont's current, quarterly and annual reports and other filings made with the U.S. Securities and Exchange Commission, in each case, as may be amended from time to time in future filings with the SEC. While the list of factors presented here is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” (Part II, Item 1A) of DuPont’s Quarterly Report on Form 10-Q for the period ended September 30, 2019 and its subsequent reports on Form 10-Q, 10-K and Form 8-K.

#########

1/9/2020

Dupont™，Dupont椭圆徽标以及用™，℠或®表示的所有商标和服务标志由Dupont de Nemours，Inc。的附属公司拥有。除非另有说明，否则除非另有说明。

有关详细信息，请联系：

杜邦媒体

丹特纳

+1 302-996-8372

daniel.a.turner@dupont.com